Sanwa and Kowa's DPP-4 licensing deal goes global

Sanwa Kagaku Kenkyushohas granted fellow Japanese firm [C#200200841:Kowa]exclusive development and marketing rights to its antidiabetic DPP-4 inhibitor, SK-0403, in all markets worldwide excluding South Korea, China and Taiwan. The agreement extends an August co-development and co-commercialisation alliance for Japan, where SK-0403 is in Phase II trials. Sanwa will receive undisclosed upfront, milestone and royalty payments. [C#200200841:Kowa] recently extended its US marketing capability through the acquisition of [C#200500155:ProEthic] Pharmaceuticals in August (Scrip Online, August 5th, 2008).

Sanwa Kagaku Kenkyushohas granted fellow Japanese firm Kowaexclusive development and marketing rights to its antidiabetic DPP-4 inhibitor, SK-0403, in all markets worldwide excluding South Korea, China and Taiwan. The agreement extends an August co-development and co-commercialisation alliance for Japan, where SK-0403 is in Phase II trials. Sanwa will receive undisclosed upfront, milestone and royalty payments. Kowa recently extended its US marketing capability through the acquisition of ProEthic Pharmaceuticals in August (Scrip Online, August 5th, 2008).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Focus On Asia

Q2 Korea Biotech Roundup: Licensing Deals End, Trials Progress, IPOs Recover

 
• By 

Aside from several sizable global out-licensing deals, South Korean bioventures saw a cancellation of other alliances, updated their pipelines with losses and gains and reported clinical trial progress in the second quarter, while domestic IPO sentiment also improved.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

Asia Deal Watch: JCR And Alexion Build Upon Existing Gene Therapy Alliances

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.

More from Scrip

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.